



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

26 January 2022  
EMA/HMPC/18311/2022  
Committee on Herbal Medicinal Products (HMPC)

## Addendum to Assessment report on *Cassia senna* L., *Cassia angustifolia* Vahl, fructus

Rapporteur(s)	J. Wiesner
Peer-reviewer	H. Foth / I. Chinou
HMPC decision on review of monograph <i>Cassia senna</i> L., <i>Cassia angustifolia</i> Vahl, fructus adopted on 25 September 2018	24 November 2021
Adoption by Committee on Herbal Medicinal Products (HMPC)	26 January 2022

### Review of new data on *Cassia senna* L., *Cassia angustifolia* Vahl, fructus

#### Unscheduled review

Data submitted by J. Wiesner to HMPC on 26 January 2022

- ☐ Safety data
- ☒ Other scientific data (*in vivo* Comet assays with aloe-emodin)
- ☐ Regulatory practice
- ☐ Referral
- ☐ Other

**Official address** Domenico Scarlattilaan 6 • 1083 HS Amsterdam • The Netherlands

**Address for visits and deliveries** Refer to [www.ema.europa.eu/how-to-find-us](http://www.ema.europa.eu/how-to-find-us)

**Send us a question** Go to [www.ema.europa.eu/contact](http://www.ema.europa.eu/contact) **Telephone** +31 (0)88 781 6000

An agency of the European Union



**Availability of new information (i.e. likely to lead to a relevant change of the monograph)**

<i>Scientific data</i>	Yes	No
New non-clinical safety data likely to lead to a relevant change of the monograph	<input type="checkbox"/>	<input checked="" type="checkbox"/>
New clinical safety data likely to lead to a relevant change of the monograph	<input type="checkbox"/>	<input checked="" type="checkbox"/>
New data introducing a possibility of a new list entry	<input type="checkbox"/>	<input checked="" type="checkbox"/>
New clinical data regarding the paediatric population or the use during pregnancy and lactation likely to lead to a relevant change of the monograph	<input type="checkbox"/>	<input checked="" type="checkbox"/>
New clinical studies introducing a possibility for new WEU indication/preparation	<input type="checkbox"/>	<input checked="" type="checkbox"/>
Other scientific data likely to lead to a relevant change of the monograph	<input type="checkbox"/>	<input checked="" type="checkbox"/>
<i>Regulatory practice</i>	Yes	No
New herbal substances/preparations with 30/15 years of TU	<input type="checkbox"/>	<input checked="" type="checkbox"/>
New herbal substances/preparations with 10 years of WEU	<input type="checkbox"/>	<input checked="" type="checkbox"/>
Other regulatory practices likely to lead to a relevant change of the monograph	<input type="checkbox"/>	<input checked="" type="checkbox"/>
Referrals likely to lead to a relevant change of the monograph	<input type="checkbox"/>	<input checked="" type="checkbox"/>
New / Updated Ph. Eur. monograph likely to lead to a relevant change of the monograph	<input type="checkbox"/>	<input checked="" type="checkbox"/>
<i>Consistency</i>	Yes	No
New or revised public statements or other HMPC decisions likely to lead to a relevant change of the monograph	<input type="checkbox"/>	<input checked="" type="checkbox"/>
Relevant inconsistencies with other monographs within the therapeutic area that require a change of the monograph	<input type="checkbox"/>	<input checked="" type="checkbox"/>
Other relevant inconsistencies that require a change of the monograph	<input type="checkbox"/>	<input checked="" type="checkbox"/>

**Summary and conclusions on the review**

During the review, two new references not yet available during the first/previous assessment were identified.

Two references were considered to be relevant for the assessment.

No references justify a revision of the monograph.

No revision is considered required because there is no references that would trigger a change in the existing wording of the monograph in section 5.3 Preclinical safety data.

**Scientific data**Non-clinical toxicology:

Nesslany *et al.* (2009) performed an *in vivo* mouse comet assay on both isolated kidney and colon cells in order to demonstrate a possible organospecific genotoxicity after oral administration of aloe-emodin (AE). Furthermore, an Ames test and an *in vitro* micronucleus assay with TK6 human lymphoblastoid cells were performed in their microscale version both with S9 from Aroclor 1254-induced liver or kidney, and without S9.

AE induced primary DNA damage in the liver and in the kidney as observed between 3 and 6 hours after two oral administrations at 500, 1000 and 2000 mg/kg bw, underlining an *in vivo* genotoxic mechanism of action. Furthermore, AE induced a clear genotoxic activity both in the *Salmonella typhimurium* strains TA1537 and TA98 and in the *in vitro* micronucleus assay in the absence as well as in the presence of metabolic activation. As no significant variation in the genotoxic activity of AE was noted when using either liver or kidney S9-mix, it seems that no quantitatively and/or qualitatively

specific renal metabolism occurs. The kidney may be a target organ of AE as it is the major route of excretion. The authors concluded that AE present in plant extracts should be considered as an *in vivo* genotoxin and this property should be taken into account in the risk assessment for human exposure.

*Assessor's comment:*

*In the study Nesslany et al. (2009) the effects on kidney cells were only seen at highest dosage. Therefore, dose relation-ship is questionable and according to OECD 489, the response is neither clearly negative nor clearly positive. Also for the effects on the colon cells, there is no clear dose-response relationship. Therefore, according to the OECD 489, these results should also be interpreted with caution. With this, not all 3 conditions needed for a positive result according to OECD 489 are met. In OECD 489, it is mentioned: "In case the response is neither clearly negative nor clearly positive (i.e. not all the criteria listed in paragraphs 59 or 60 are met) and in order to assist in establishing the biological relevance of a result, the data should be evaluated by expert judgement and/or further investigations conducted, if scientifically justified.". From our point of view, the absolute conclusion drawn by the authors could therefore not be followed without any doubt. Therefore, the results could at most be seen as a "trend".*

Galli et al. (2021) conducted a new *in vivo* study (*in vivo* alkaline comet assay in mice -OECD 489) to test the potential genotoxicity of aloe-emodin at doses of 250, 500, 1000 and 2000 mg/kg bw/day on preparations of single cells from the kidney and colon of treated male mice. Following treatment with the test item, no clinical signs were observed in animals in any treatment group. Slight bodyweight loss was randomly observed in all groups treated with the test item and was more evident in the groups dosed at 1000 and 2000 mg/kg bw/day. Under these experimental conditions, aloe-emodin showed no genotoxic activity. The authors mentioned that possible oxidative damage to colon tissues could not be excluded based on the results obtained after repair enzyme treatment and they hypothesised that the mechanism of action for HADs is more to be seen in a tumour promoting effect at a diarrheagenic doses, rather than a mechanism mediated by a genotoxic effect.

*Assessor's comment:*

*Aloe-emodin did not induce DNA damage in preparation of single cells from colon and kidneys following oral gavage at doses of 250, 500, 1000, and 2000 mg/kg/day under the standard reported experimental conditions. Furthermore, no statistically significant increases in tail moment and tail intensity were observed over those in the vehicle-treated control group at any dose level.*

*For colon tissue (kidney cells were negative), following the enzymatic treatment, statistically significant increases in break sites were observed above 500 mg/kg bw/day, although no dose-response relationship was identified.*

## **General assessment in relation to the monograph of the HMPC**

Overall, the results of the two *in vivo* studies do not trigger an unscheduled revision of the monograph since results of the Comet assays on aloe-emodin revealed no, or inconclusive, genotoxic effects. To ensure that the potential genotoxic suspicion can be clearly eliminated, more experimental data on characterised materials are needed. Until genotoxic effects are ruled out without doubt, also the contraindications etc. should be kept.

## **References**

a) References relevant for the assessment:

Nesslany F, Simar-Meintières S, Ficheux H, Marzin D. Aloe-emodin-induced DNA fragmentation in the mouse *in vivo* comet assay. *Mutat Res.* 2009, 678(1):13-9, in press, doi: 10.1016/j.mrgentox.2009.06.004

Galli CL, Cinelli S, Ciliutti P, Melzi G, Marinovich M. Aloe-emodin, a hydroxyanthracene derivative, is not genotoxic in an *in vivo* comet test. *Regul Toxicol Pharmacol*. 2021(a), 124:104967, in press, doi: 10.1016/j.yrtph.2021.104967

b) References that justify the need for the revision of the monograph:

None

**Rapporteur's proposal on revision**

- ☐ Revision needed, i.e. new data/findings of relevance for the content of the monograph
- ☒ No revision needed, i.e. no new data/findings of relevance for the content of the monograph

**HMPC decision on revision**

- ☐ Revision needed, i.e. new data/findings of relevance for the content of the monograph
- ☒ No revision needed, i.e. no new data/findings of relevance for the content of the monograph

The HMPC agreed not to revise the monograph, assessment report and list of references on *Cassia senna* L., *Cassia angustifolia* Vahl, fructus, by majority.

The following members did not agree with the decision of the HMPC and were of the position that there are new data/findings of relevance for the content of the monograph and a revision is needed:

Wojciech Dymowski, Poland.